Vitrolife Group (VITR) Q1 2025 earnings summary

Executive summary

• Net sales reached SEK 842 million, up 1% in local currencies and flat in SEK; excluding discontinued business, growth was 3% in local currencies.

• Gross margin improved to 57.4% from 57.1% year-over-year.

• EBITDA was SEK 257 million (30.6% margin), down from SEK 272 million (32.4%) due to FX and higher selling expenses.

• Net income declined to SEK 100 million, with EPS at SEK 0.74, compared to SEK 0.85 last year.

• EMEA and Americas delivered strong organic growth (EMEA: 14% excluding discontinued business, Americas: 9%), while APAC declined 15% due to high comparables and cultural cycle timing.

Financial highlights

• Sales: SEK 842 million, up 1% in local currencies (3% excluding discontinued business).

• Gross income: SEK 483 million, margin 57.4%.

• EBITDA margin: 30.6% (down from 32.4%).

• Net income: SEK 100 million, down from SEK 150 million year-over-year.

• Operating cash flow: SEK 69 million, down from SEK 198 million, mainly due to working capital changes.

Outlook and guidance

• Expectation of continued strong momentum in EMEA and Americas, with APAC cycle numbers anticipated to normalize as the year progresses.

• IVF cycles expected to grow mid-single digit globally, supported by declining fertility rates and improved reimbursement.

• Tariff and sanction impacts are being managed through cost containment and selective price increases; some costs will be passed on to customers.

• Focus remains on growth, innovation, and operational excellence, with investments in automation and digitalization.